Scottsdale 2/15/2014 4:00:00 AM
QualityStocks News - Boston Therapeutics (BTHE) Inks Consulting Agreement to Launch SugarDown® in U.S. Market
QualityStocks would like to highlight Boston Therapeutics (OTCQB: BTHE), a pharmaceutical company focused on the development and commercialization of novel compounds based on complex carbohydrate chemistry to address unmet medical needs. An IP portfolio solidifies the company's position in the pharmaceutical industry. Boston Therapeutics' current product pipeline, PAZ320 and IPOXYNT, is comprised of therapies developed to treat patient populations with Type 2 diabetes.
In the company’s news,
Boston Therapeutics has signed a consulting agreement with Generosus Advisors, LLC and Fortified Management Group, LLC to market the SugarDown® dietary supplement in the United States on a non-exclusive basis.
SugarDown® is intended to support healthy blood sugar. In clinical studies the product demonstrated its capability to reduce after meal sugar spikes. Marketing efforts of SugarDown® will be conducted through the Help Now Network (HNN), a healthcare marketing company and its affiliates. Fulfillment of all customer orders for SugarDown® will also be managed by HNN, as well as other direct distribution channels.
HNN maintains a database through its affiliate of approximately 2 million members, many of whom fit the SugarDown® market demographic. SugarDown® will be test-marketed to this member-base via trained outbound call center outreach and electronic media.
“In our marketing agreement for SugarDown® in the United States, we are working with a company that has a broad knowledge of the needs of those who fit our ideal customer profile,” Kenneth A. Tassey, Jr., president of Boston Therapeutics, stated in the news release. “HNN has created an impressive database of loyal members. We are confident that HNN will effectively communicate the benefits of SugarDown® to these individuals and efficiently distribute the product when orders are placed.”
Thomas Scipione of HNN further explained the marketing company’s experience with other products targeting diabetes management.
“We are very excited to introduce SugarDown® to our two million members. Over the past several years we have marketed many products that are beneficial to our members to help them better manage their disease. We plan to rollout a marketing campaign for SugarDown® in the next few weeks. Help Now Networks is in the business of lead generation through digital media and telemarketing services. For the past five years HNN’s primary focus has been in healthcare of which diabetes has been our core campaign,” said Scipione.
About QualityStocks
QualityStocks, based in Scottsdale, Arizona, is a free service that collects data from hundreds of Small-Cap and Micro-Cap online Investment Newsletters into one Daily Newsletter Report. QualityStocks is dedicated to assisting emerging public companies with their investor communication efforts and connecting subscribers with companies that have huge potential to succeed in the short and long-term future.
To sign up for The QualityStocks Daily Newsletter, please visit www.QualityStocks.net
To connect with QualityStocks via Facebook, please visit http://Facebook.com/QualityStocksPage
To connect with QualityStocks via Twitter, please visit http://Twitter.com/QualityStocks
Please read FULL disclaimer on the QualityStocks website: http://Disclaimer.QualityStocks.net
Forward-Looking Statement:
This release may contain forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. All forward-looking statements are inherently uncertain as they are based on current expectations and assumptions concerning future events or future performance of the company. Readers are cautioned not to place undue reliance on these forward-looking statements, which are only predictions and speak only as of the date hereof. Risks and uncertainties applicable to the company and its business could cause the company's actual results to differ materially from those indicated in any forward-looking statements.
